Komori
Share Issuance and Disposal4583Chiome Bioscience Inc.Pharmaceuticals

Notice Regarding the Monthly Exercise Status of the 23rd Stock Acquisition Rights (with Exercise Price Adjustment Clause)

The exercise results for the 23rd Stock Acquisition Rights in April 2026 have been reported. A total of 1,808,000 shares were delivered during April, leaving 7,204,500 shares unexercised at month-end.

Worth reading
66In focus
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1808000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly report on the exercise status of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数

Number of shares delivered during the month: 1,808,000 shares (all newly issued shares; treasury shares transferred: 0 shares)

発行済株式総数

Exercise ratio during the month: 13.29% (ratio to the total number issued); exercise ratio relating to exercise restrictions: 2.66% (number of shares delivered during the month / number of listed shares as of the payment date for the issuance)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise price during the month: ¥92.0–¥95.7. Lower limit under the adjustment clause: Not disclosed
Number of Stock Acquisition Rights
Total number issued: 136,000; unexercised balance at the end of the preceding month: 90,125; unexercised balance at the end of the month: 72,045
Procedures under the Corporate Code of Conduct
Report on compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Rules on Listing of Securities and the Japan Securities Dealers Association's Rules Concerning Handling of Third-Party Allotments and Other Matters
Most recent equity financing
23rd Stock Acquisition Rights issued on 15 December 2025 (with exercise price adjustment clause)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly report on the exercise status of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed ofNumber of shares delivered during the month: 1,808,000 shares (all newly issued shares; treasury shares transferred: 0 shares)
Dilution RateExercise ratio during the month: 13.29% (ratio to the total number issued); exercise ratio relating to exercise restrictions: 2.66% (number of shares delivered during the month / number of listed shares as of the payment date for the issuance)
Exercise priceExercise price during the month: ¥92.0–¥95.7. Lower limit under the adjustment clause: Not disclosed
Number of Stock Acquisition RightsTotal number issued: 136,000; unexercised balance at the end of the preceding month: 90,125; unexercised balance at the end of the month: 72,045
Procedures under the Corporate Code of ConductReport on compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Rules on Listing of Securities and the Japan Securities Dealers Association's Rules Concerning Handling of Third-Party Allotments and Other Matters
Most recent equity financing23rd Stock Acquisition Rights issued on 15 December 2025 (with exercise price adjustment clause)
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status of the 23rd Stock Acquisition Rights in April 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 23rd Stock Acquisition Rights (with Exercise Price Adjustment Clause) | Chiome Bioscience Inc. (4583) timely disclosure | Komori